m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02853)
Name
GHRP-2
Synonyms
Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy
    Click to Show/Hide
Status
Approved
Structure
3D MOL
2D MOL
Formula
C45H55N9O6
InChI
1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
InChIKey
HRNLPPBUBKMZMT-RDRUQFPZSA-N
PubChem CID
6918245
TTD Drug ID
D08VRX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Phosphogluconate dehydrogenase (PGD)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Phosphogluconate dehydrogenase (PGD) is a therapeutic target for GHRP-2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GHRP-2 through regulating the expression of Phosphogluconate dehydrogenase (PGD). [1], [2]
References
Ref 1 YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020 Jul 10;41(5):541-550. doi: 10.1093/carcin/bgz152.
Ref 2 Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. doi: 10.1016/j.bmc.2010.04.087. Epub 2010 Apr 29.